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INTRODUCTION: It has been suggested that altered metabolism may contribute to lumbar disc 
degeneration (DD). Quantitative high-throughput serum nuclear magnetic resonance (NMR) 
metabolomics has recently been introduced as a cost-effective way to obtain comprehensive data 
on systemic metabolism. Here we report our preliminary work on the identification of serum 
metabolomic biomarkers in relation to lumbar DD, with a primary focus on small molecules and 
lipid extracts. 
 
METHODS: A radiographic and clinical cross-sectional study of 810 Southern Chinese 
volunteers was performed. A serum NMR metabolomics platform was utilized to assess the 
systemic metabolic profiles (~150 metabolic measures for each individual). Sagittal MRIs were 
utilized to assess DD (Schneiderman criteria) from L1-S1. A summated degenerative disc disease 
(DDD) score of the lumbar levels was obtained. Subject demographics and 
environmental/lifestyle factors were also assessed. ROC analysis and multivariate logistic 
regression analysis were performed to determine the strength and risk of various metabolomic 
biomarkers in relation to DD. 
 
RESULTS: There were 315 male and 495 females (mean age: 51 years). DD was noted in 77% of 
the subjects. Multivariate model adjusted for age, sex, BMI, smoking status, triglycerides, ESR, 
and hs-CRP where appropriate. Serum tyrosine: lactate (OR: 1.60; 95% CI: 1.03-2.49) and 
leucine:isoleucine (OR: 2.65; 95% CI: 1.01-6.92) were significantly associated with the overall 
presence of DD. Elevated serum biomarker ratio of valine to histidine (critical value≥ 3.8; DDD 
Score ≥5; OR: 1.74; 95% CI: 1.07 -2.85) and lipid extracts (e.g. fatty acids; p<0.05) were 
significantly associated with moderate to severe DD. 
 
CONCLUSIONS: This is the first study to report on a serum metabolomics approach in relation 
to DD. Novel serum biomarkers associated with early and moderate/severe lumbar DD were 
identified. Future studies are needed to validate the findings. 
